Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Immunogenicity of STSP-0902 in Healthy Subjects

NCT06563713 is registered in ClinicalTrials.gov with Staidson (Beijing) Biopharmaceuticals Co., Ltd as lead sponsor.

NCT NCT06563713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06563713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Immunogenicity of STSP-0902 in Healthy Subjects
Lead sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2024
Completion date
February 24, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthenozoospermia, oligozoospermia